Revance Therapeutics
RVNC
$3.28
Share price
-1.36%
Change (1 day)
-90.69%
Change (1 year)
Categories
Revance Therapeutics (RVNC) - Total debt
Total debt on the balance sheet as of December 2023 : $0.47 B
According to Revance Therapeutics's latest financial reports the company's total debt is $0.47 B. A company’s total debt is the sum of all current and non-current debts.
Revance Therapeutics - Total debt on balance sheet (from 2012 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.47 B | 14.33% |
| 2022-12-31 | $0.41 B | 28.95% |
| 2021-12-31 | $0.32 B | 52.99% |
| 2020-12-31 | $0.21 B | 622.93% |
| 2019-12-31 | $29.34 M | |
| 2018-12-31 | $N/A | -100% |
| 2017-12-31 | $1.87 M | -64.99% |
| 2016-12-31 | $5.34 M | -36.95% |
| 2015-12-31 | $8.48 M | 139.58% |
| 2014-12-31 | $3.54 M | -86.11% |
| 2013-12-31 | $25.49 M | -76.05% |
| 2012-12-31 | $0.10 B | 54.3% |
| 2011-12-31 | $68.98 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $33.63 B | 6,929.60% | 🇺🇸 USA |
 Biogen BIIB | $6.94 B | 1,351.95% | 🇺🇸 USA |
 MediciNova MNOV | $0.21 M | -99.95% | 🇺🇸 USA |